[Tadalafil: novel aspects of phosphodiesterase-5 inhibition in the treatment of pulmonary hypertension].
Tadalafil, which was commercialized in 2009, is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor, and may be a safe and effective therapeutic alternative for patients with class II and III pulmonary hypertension (PH) in the World Health Organization's classification--as stated in the Clinical Practice Guidelines for the Diagnosis and Treatment of PH of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)--providing benefits in exercise tolerance, delaying clinical deterioration and improving quality of life. Given the greater half-life of this drug, allowing a single oral dose of 40 mg per day, tadalafil could improve therapeutic compliance--thus facilitating treatment adherence--among patients with PH.
Servicio de Neumología, Hospital Ramón y Cajal, Madrid, España. Electronic address: jgaudo.hrc@salud.madrid.org.
Javier
J
Gaudó Navarro
Antonio
A
Sueiro Bendito
D002243:Carbolines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006152:Cyclic GMP / Q000378:metabolism; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5 / Q000502:physiology; D004311:Double-Blind Method; D004347:Drug Interactions; D017079:Exercise Tolerance / Q000187:drug effects; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000201:enzymology; D015394:Molecular Structure; D058986:Phosphodiesterase 5 Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D011379:Prognosis; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D015290:Second Messenger Systems; D000068581:Tadalafil
D002243:Carbolines; D058986:Phosphodiesterase 5 Inhibitors; D000068581:Tadalafil; D054706:Cyclic Nucleotide Phosphodiesterases, Type 5; D006152:Cyclic GMP